Bristol-Myers Squibb Co. (BMY) PT Lowered to $58 at Barclays
Get Alerts BMY Hot Sheet
Price: $54.23 +1.84%
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Barclays lowered its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $58.00 (from $65.00) while maintaining a Equalweight rating.
Analyst Dr. Geoff Meacham comments "We expect BMY to be the leader in immuno-oncolog, but the failure of CheckMate-026 limits near term market penetration in lung cancer. Given the delay in the revenue and EPS ramp until 2018/2019, we believe significant multiple expansion is unlikely absent clinical data that improves visibility on the growth trajectory."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- UPS (UPS) PT Lowered to $150 at HSBC, 'on lower multiple to reflect continued de-rating'
- DouYu (DOYU) PT Lowered to $0.60 at Citi
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!